

Marie Wislez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1205925/publications.pdf>

Version: 2024-02-01

129
papers

7,789
citations

61687

45
h-index

62345

84
g-index

169
all docs

169
docs citations

169
times ranked

11810
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Prognostic Factors in Localized NSCLC. <i>Cancers</i> , 2022, 14, 1400.	1.7	28
2	Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 199-211.	1.8	10
3	Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 807-816.	0.5	11
4	Short-term and Long-term Outcomes of Patients With Lung Cancer and Life-Threatening Complications. <i>Chest</i> , 2021, 160, 1560-1564.	0.4	10
5	The rising challenge of oncogene addiction in lung cancer. <i>Bulletin Du Cancer</i> , 2021, 108, 559-561.	0.6	0
6	Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features. <i>Lung Cancer</i> , 2021, 156, 117-121.	0.9	3
7	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). <i>Lung Cancer</i> , 2021, 157, 124-130.	0.9	5
8	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. <i>Clinical Medicine</i> , 2021, 21, e552-e555.	0.8	1
9	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	0.8	32
10	Immunodynamics of explanted human tumors for immunoncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	3.3	9
11	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. <i>Cancers</i> , 2021, 13, 5132.	1.7	9
12	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. <i>EBioMedicine</i> , 2021, 73, 103630.	2.7	6
13	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , 2020, 39, 1893-1899.	2.3	16
14	The impact of body composition parameters on severe toxicity of nivolumab. <i>European Journal of Cancer</i> , 2020, 124, 170-177.	1.3	32
15	Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	130
16	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). <i>European Journal of Cancer</i> , 2020, 141, 62-81.	1.3	122
17	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 497-505.	1.1	7
18	Capmatinib-induced interstitial lung disease: A case report. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100024.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Risk of scleroderma according to the type of immune checkpoint inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102596.	2.5	44
20	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100052.	0.6	9
21	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	1.7	72
22	Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 860-866.	0.5	84
23	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). <i>Lung Cancer</i> , 2019, 136, 109-114.	0.9	16
24	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 844-856.	0.5	55
25	Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?. <i>Bulletin Du Cancer</i> , 2019, 106, 725-733.	0.6	2
26	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	1.7	28
27	Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. <i>Bulletin Du Cancer</i> , 2019, 106, 179-188.	0.6	1
28	Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. <i>Aids</i> , 2018, 32, 461-468.	1.0	21
29	Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. <i>Thorax</i> , 2018, 73, 145-150.	2.7	140
30	Lung cancer and interstitial lung disease: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, 3829-3844.	0.6	126
31	c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1962-1967.	0.5	48
32	TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5710-5723.	3.2	257
33	P2.03b-037 Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S957-S958.	0.5	0
34	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1286437.	2.1	28
35	Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. <i>Nature</i> , 2017, 545, 360-364.	13.7	336
36	Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	83

#	ARTICLE	IF	CITATIONS
37	Lymphoproliferative Disorders of the Lung. <i>Respiration</i> , 2017, 94, 157-175.	1.2	48
38	P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSA© Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1182-S1183.	0.5	2
39	P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1219-S1220.	0.5	2
40	OA06.05 Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S265-S266.	0.5	0
41	Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma. <i>ERJ Open Research</i> , 2017, 3, 00047-2016.	1.1	13
42	Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 105103-105114.	0.8	27
43	MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. <i>Oncotarget</i> , 2017, 8, 42428-42437.	0.8	47
44	Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 103744-103757.	0.8	24
45	Immunotherapy's new challenge: identification of predictive biomarkers for tumor response. <i>Translational Cancer Research</i> , 2017, 6, S306-S308.	0.4	0
46	Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2016, 7, 83.	1.3	6
47	Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?. <i>Annals of Translational Medicine</i> , 2016, 4, 96-96.	0.7	4
48	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. <i>Lung Cancer</i> , 2016, 98, 51-58.	0.9	110
49	Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility. <i>Cell</i> , 2016, 166, 328-342.	13.5	304
50	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016, 48, 1252-1252.	3.1	11
51	EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. <i>Lung Cancer</i> , 2016, 96, 74-77.	0.9	15
52	Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. <i>European Respiratory Journal</i> , 2016, 48, 861-872.	3.1	17
53	NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma. <i>Cancer Medicine</i> , 2016, 5, 3579-3585.	1.3	31
54	Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?. <i>European Respiratory Journal</i> , 2016, 47, 1890-1891.	3.1	1

#	ARTICLE	IF	CITATIONS
55	Sonic Hedgehog Pathway Activation Is Associated With Resistance to Platinum-Based Chemotherapy in Advanced Nonâ€‘Small-Cell Lung Carcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, 301-308.	1.1	38
56	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016, 47, 1244-1260.	3.1	60
57	Screening for mutations in lung cancer in France: purpose of precision medicine. <i>Translational Cancer Research</i> , 2016, 5, S47-S49.	0.4	0
58	Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1148-1155.	0.5	48
59	Brain Metastasis in Patients with Non-Small Cell Lung Cancer: Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. , 2015, , 59-67.		0
60	Erlotinibversuscarboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. <i>European Respiratory Journal</i> , 2015, 46, 1440-1450.	3.1	7
61	Human RNA polymerase II associated factor 1 complex promotes tumorigenesis by activating c-MYC transcription in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 465, 685-690.	1.0	17
62	Expression of TLR9 in tumorâ€‘infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. <i>International Journal of Cancer</i> , 2014, 134, 765-777.	2.3	35
63	Factors associated with early progression of nonâ€‘smallâ€‘cell lung cancer treated by epidermal growth factor receptor tyrosineâ€‘kinase inhibitors. <i>Cancer Medicine</i> , 2014, 3, 61-69.	1.3	6
64	The PI3K/AKT pathway promotes gefitinib resistance in mutant <i>KRAS</i> lung adenocarcinoma by a deacetylaseâ€‘dependent mechanism. <i>International Journal of Cancer</i> , 2014, 134, 2560-2571.	2.3	50
65	VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. <i>MAbs</i> , 2014, 6, 1638-1648.	2.6	30
66	Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. <i>Lung Cancer</i> , 2014, 85, 276-281.	0.9	62
67	Customized Adjuvant Phase II Trial in Patients With Nonâ€‘Small-Cell Lung Cancer: IFCT-0801 TASTE. <i>Journal of Clinical Oncology</i> , 2014, 32, 1256-1261.	0.8	66
68	The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation. <i>Lung Cancer</i> , 2014, 83, 334-340.	0.9	25
69	Prospective screening for ALK: Clinical features and outcome according to ALK status. <i>European Journal of Cancer</i> , 2014, 50, 1239-1246.	1.3	46
70	Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 477-493.	2.0	71
71	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	0.8	572
72	Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1574-1577.	0.5	165

#	ARTICLE	IF	CITATIONS
73	Crizotinib : l'Ã©tude de phase III confirme notre pratique quotidienne. Bulletin Du Cancer, 2013, 100, 939.	0.6	1
74	Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy. PLoS ONE, 2013, 8, e60816.	1.1	28
75	Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient. Journal of Thoracic Oncology, 2012, 7, 1061-1063.	0.5	21
76	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. Journal of Thoracic Oncology, 2012, 7, 1423-1431.	0.5	9
77	MALT1 Rearrangements in BAL Fluid. Chest, 2012, 142, 262.	0.4	1
78	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502.	0.5	69
79	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. Molecular Cancer Therapeutics, 2012, 11, 1203-1213.	1.9	77
80	Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respiriology, 2012, 17, 134-142.	1.3	43
81	Treatment of recurrent respiratory papillomatosis lung involvement by cidofovir infusion. Scandinavian Journal of Infectious Diseases, 2011, 43, 112-114.	1.5	3
82	Clonality and phenotyping analysis of alveolar lymphocytes is suggestive of pulmonary MALT lymphoma. Respiratory Medicine, 2011, 105, 1231-1237.	1.3	26
83	Ã©volution histologique et gÃ©notypique des cancers bronchiques non Ã© petites cellules (CBNPC) avec rÃ©sistance acquise sous TKI EGFR. Bulletin Du Cancer, 2011, 98, 1379-1380.	0.6	0
84	Skin Toxicities Compromise Prolonged Pemetrexed Treatment. Journal of Thoracic Oncology, 2011, 6, 2083-2089.	0.5	39
85	Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Journal of Pathology, 2011, 225, 83-95.	2.1	43
86	Release of Metal Particles From Needles Used for Transbronchial Needle Aspiration. Chest, 2011, 139, 138-143.	0.4	30
87	101: Identification of differential pathways in mucinous and non-mucinous subtypes of lung adenocarcinoma suggested new therapeutic strategies. Bulletin Du Cancer, 2010, 97, S81-S82.	0.6	2
88	Fluorine-18 Fluorodeoxyglucose with Positron Emission Tomography Revealed Bone Marrow Involvement in Sarcoidosis Patients with Anaemia. Respiration, 2010, 79, 25-31.	1.2	17
89	Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination. Molecular Cancer Therapeutics, 2010, 9, 358-368.	1.9	44
90	Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer, 2010, 68, 185-191.	0.9	77

#	ARTICLE	IF	CITATIONS
91	Imaging of Hereditary Hemorrhagic Telangiectasia. CardioVascular and Interventional Radiology, 2009, 32, 745-757.	0.9	42
92	Pemetrexed-Induced Pneumonitis: A Case Report. Clinical Lung Cancer, 2009, 10, 364-366.	1.1	14
93	A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant <i>K-ras</i> . Molecular Cancer Therapeutics, 2008, 7, 952-960.	1.9	64
94	Intratumoral Epiregulin Is a Marker of Advanced Disease in Non-Small Cell Lung Cancer Patients and Confers Invasive Properties on <i>EGFR</i> -Mutant Cells. Cancer Prevention Research, 2008, 1, 201-207.	0.7	59
95	Long-Term Survival for Patients With Non-Small-Cell Lung Cancer With Intratumoral Lymphoid Structures. Journal of Clinical Oncology, 2008, 26, 4410-4417.	0.8	797
96	Gefitinib-Associated <i>Propionibacterium acnes</i> Pleural Empyema. Journal of Thoracic Oncology, 2008, 3, 556-557.	0.5	10
97	Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic <i>K-ras</i> -Induced Lung Cancer. PLoS ONE, 2008, 3, e2220.	1.1	73
98	The intersection of EGFR and the Ras signaling pathway. , 2008, , 84-90.		1
99	Neutrophils Promote Aerogenous Spread of Lung Adenocarcinoma with Bronchioloalveolar Carcinoma Features. Clinical Cancer Research, 2007, 13, 3518-3527.	3.2	46
100	Impact of Randomized Clinical Trials on Clinical Practice Regarding Treatment of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 456.	0.5	2
101	Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines. American Journal of Pathology, 2007, 170, 366-376.	1.9	141
102	Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer, 2007, 58, 425-428.	0.9	40
103	Lung cancer, a new challenge in the HIV-infected population. Lung Cancer, 2006, 51, 1-11.	0.9	53
104	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359.	0.5	33
105	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12.	0.5	6
106	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359.	0.5	80
107	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12.	0.5	14
108	High Expression of Ligands for Chemokine Receptor CXCR2 in Alveolar Epithelial Neoplasia Induced by Oncogenic <i>Kras</i> . Cancer Research, 2006, 66, 4198-4207.	0.4	151

#	ARTICLE	IF	CITATIONS
109	The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. <i>Journal of Thoracic Oncology</i> , 2006, 1, 344-59.	0.5	21
110	Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. <i>Journal of Thoracic Oncology</i> , 2006, 1, S8-12.	0.5	2
111	Murine Lung Tumor Measurement Using Respiratory-Gated Micro-Computed Tomography. <i>Investigative Radiology</i> , 2005, 40, 263-269.	3.5	65
112	Inhibition of Mammalian Target of Rapamycin Reverses Alveolar Epithelial Neoplasia Induced by Oncogenic <i>K-ras</i> . <i>Cancer Research</i> , 2005, 65, 3226-3235.	0.4	158
113	High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor. <i>Cancer Research</i> , 2005, 65, 11478-11485.	0.4	135
114	Sarcoidosis in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, 418-425.	2.9	102
115	Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array. <i>Clinical Cancer Research</i> , 2004, 10, 3479-3489.	3.2	277
116	Changes in the Pattern of Respiratory Diseases Necessitating Hospitalization of HIV-infected Patients Since the Advent of Highly Active Antiretroviral Therapy. <i>Lung</i> , 2004, 182, 331-341.	1.4	27
117	Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting <i>Staphylococcus aureus</i> . <i>Intensive Care Medicine</i> , 2003, 29, 1840-1843.	3.9	97
118	Improvement of Symptomatic Human Immunodeficiency Virus-Related Lymphoid Interstitial Pneumonia in Patients Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2003, 36, e127-e130.	2.9	49
119	Clinical Characteristics of Pneumonic-Type Adenocarcinoma of the Lung. <i>Chest</i> , 2003, 123, 1868-1877.	0.4	96
120	Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. <i>Cancer Research</i> , 2003, 63, 1405-12.	0.4	190
121	Nodular Densities after HAART Introduction in an AIDS Patient. <i>Respiration</i> , 2002, 69, 283-285.	1.2	4
122	Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Prolong the Survival of Neutrophils Infiltrating Bronchoalveolar Subtype Pulmonary Adenocarcinoma. <i>American Journal of Pathology</i> , 2001, 159, 1423-1433.	1.9	63
123	AIDS-Related Alveolar Hemorrhage. <i>Chest</i> , 2001, 120, 1078-1084.	0.4	27
124	Acute Respiratory Failure Following HAART Introduction in Patients Treated for <i>Pneumocystis carinii</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 847-851.	2.5	133
125	Spectrum of CD4 to CD8 T-Cell Ratios in Lymphocytic Alveolitis Associated with Methotrexate-induced Pneumonitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1186-1191.	2.5	67
126	Organizing Pneumonia Related to Common Variable Immunodeficiency. <i>Respiration</i> , 2000, 67, 467-470.	1.2	26

#	ARTICLE	IF	CITATIONS
127	Sarcoid-like Pulmonary Disorder in Human Immunodeficiency Virusâ€“infected Patients Receiving Antiretroviral Therapy. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 2009-2013.	2.5	112
128	Pulmonary Malignancies in the Immunocompromised Patient. Respiration, 1999, 66, 289-309.	1.2	55
129	AIDS-related Primary Pulmonary Lymphoma. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1221-1229.	2.5	61